JP Morgan Chase’s Pelthos Therapeutics PTHS Stock Holding History

JP Morgan Chase’s Portfolio PTHS Stock Details PTHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$28	–	7846
2025 Q3	$28	Buy	+1	New	+$24	﹤0.01%	7269

Other funds holding PTHS

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase's PTHS Position: Q4 2025 in Review

JP Morgan Chase sold out of Pelthos Therapeutics (PTHS) in Q4 2025, closing a stake of 1 share — an estimated $28 sold.

JP Morgan Chase first reported a position in PTHS in Q3 2025 and held it in 1 quarter. The position peaked at $28 in Q3 2025. 15 funds tracked by Wall St. Rank hold PTHS as of Q4 2025.

JP Morgan Chase reported no remaining Pelthos Therapeutics position as of Q4 2025 after selling out during the quarter.
JP Morgan Chase sold 1 Pelthos Therapeutics share in Q4 2025, an estimated $28.
JP Morgan Chase first reported a position in Pelthos Therapeutics in Q3 2025 and held it in 1 quarter.
JP Morgan Chase's Pelthos Therapeutics position peaked at $28 in Q3 2025.
15 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.